Leqselvi is now FDA approved for treating severe alopecia areata. Sun Pharma added the oral drug to its pipeline via the $576 million acquisition of Concert Pharmaceuticals last year.
Sun Pharmaceuticals is acquiring Concert Pharmaceuticals, a biotech whose lead program has positive data from two late-stage clinical trials in alopecia areata. The deal gives Sun Pharma a drug candidate that could match up against hair loss drugs from two big pharmaceutical companies.
In a recent interview, Esperion president and CEO, Sheldon Koenig talks about the reality of statin intolerance and his company’s expansion into new diseases